Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible

HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced the appointment of Adriano Treve as a Strategic Advisor for partnerships.

Read more at globenewswire.com